Pages

Wednesday, 21 November 2012

Optegra to introduce end-stage AMD treatment to the UK


Optegra to introduce end-stage AMD treatment to the UK

NOVEMBER 15 2012
Specialist eye hospital group Optegra has signed an agreement which will allow its surgeons to offer the first-ever FDA-approved ophthalmic telescope implant to patients at the end stage of AMD.
Optegra has partnered with American-based ophthalmic specialists VisionCare Ophthalmic Technologies to introduce the treatment option to the UK. 
The implantable miniature telescope uses micro-optical technology to magnify images which would not normally be visible in the central vision of someone with the end stages of AMD.  The images are magnified onto a part of the retina not affected by the disease, allowing patients to see the object. 
The device, which is smaller than a pea, is the only medical option which improves visual acuity by reducing the impact of the central vision blind spot. 
Gareth Steer, managing director of Optegra, said: “We are committed to being at the forefront of medical treatment options, and this latest offering really captures how we have the best surgeons available to offer the best treatments for any eye conditions.”
The treatment will initially be offered at Optegra’s Surrey, Solent and Manchester eye hospitals, and performed by ophthalmic consultants Andy Luff and Brendan Moriarty. 
“While there is no absolute cure for AMD, the symptoms of end stage AMD can be so debilitating we are confident that we can make a real difference to people’s lives by offering this new, highly advanced procedure.”